Pharmacokinetics Study of Gamma-aminobutyric Acid

Diabetes Mellitus Clinical Trial

— GABA-PK  

Official title:

The Pharmacokinetics of Gamma-aminobutyric Acid in Healthy Volunteers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01917760
• Other study ID #: KY-2013-222
• Secondary ID: JDRF_17-2013-499
• Status: Completed
• Phase: Phase 1
• First received: July 6, 2013
• Last updated: October 30, 2015
• Start date: July 2013
• Est. completion date: December 2014

Study information

• Verified date: October 2015
• Source: Huashan Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine upon administering GABA orally to a person how it is absorbed, distributed, as well as the drug's pharmacological effects on the body such as glucose levels, serum C-peptide and/or insulin levels (referred to as pharmacokinetics/pharmacodynamics). We will conduct experiments in normal subjects to address these questions.

Description:

Type 1 diabetes is an autoimmune disease resulting from the progressive loss of pancreatic insulin-secreting beta-cells. This consequently leads to a lack of insulin and elevation of blood sugar, namely hyperglycemia, which is a major cause for the development of diabetes and its acute or chronic complications. The current treatment for type 1 diabetes requires a life-long dependency on daily insulin injections, causing inconvenience and burden to patients. Drug-induced hypoglycemia is also common as it presents a major challenge in insulin therapy. Furthermore, although insulin therapy is lifesaving, it is not a cure as it neither reverses the progression of the disease nor prevents the development of serious complications associated with this disease. New treatments are urgently needed.

Recent studies have demonstrated that a natural chemical found in the brain, gamma-aminobutyric acid (GABA), which is also produced in large quantities by pancreatic beta-cells, has beta-cell regenerative and immunoregulatory effects. Importantly, GABA prevented and partially reversed diabetes in type 1 diabetes mouse models. It is important to address essential questions regarding the potential effects of GABA in diabetic patients in humans. Given the largely unknown mechanism of action of GABA in the pancreas, and the limited information on how GABA is absorbed, distributed and eliminated from the human body, we plan to examine these issues (referred to as pharmacokinetics/pharmacodynamics) in normal subjects.

The outcome of this study will provide useful information on the mechanism of action of GABA in human subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: December 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Volunteers in good health condition between 19 and 40 years of age (inclusive) at the time of signing the informed consent.

2. Body mass index (BMI) between 18.5 and 24 kg/m2 (inclusive), with weight greater than 50 kg.

3. Not on any medication 2 weeks before screening.

4. No blood donation within 3 months before screening.

5. Must sign the informed consent. Note: Blood and biochemical tests must be normal during the screening. However, if the participant's test-results were beyond the normal range, the individual can still be recruited as long as the results do not affect the experiment.

Exclusion Criteria:

1. Abnormalities of physical examination, laboratory tests, or ECG in screening, which may influence the results of the study.

2. Previous or existing history of severe heart, liver, kidney, gastrointestinal, nervous system, mental, or metabolic abnormalities as well as other diseases which can affect drug absorption, circulation, metabolism, or excretion.

3. History of alcoholism, smoking, or drug abuse within the past 1 year.

4. Participation in any clinical drug study within the past 30 days.

5. Any definite or suspected allergy or family history of allergy to GABA or any other similar drugs.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Autoimmune Diseases
• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Endocrine System Diseases
• Glucose Metabolism Disorders
• Immune System Diseases
• Metabolic Diseases

Locations

Country	Name	City	State
China	Department of Endocrinology and Metabolism,Huashan hospital	Shanghai	Shanghai

Sponsors (4)

Lead Sponsor	Collaborator
Huashan Hospital	St. Michael's Hospital, Toronto, University of Florida, University of Massachusetts, Worcester

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory measures	plasma glucagon-like peptide-1 (GLP-1) and glycated serum protein (GSP)will be measured.	baseline and up to 30 days	No
Primary	pharmacokinetic characteristics of ?-aminobutyric acid (GABA)	The primary endpoint of this study is to obtain the pharmacokinetic characteristics of ?-aminobutyric acid (GABA), including: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t),; Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-8),; Maximum observed plasma concentration (Cmax),; Time to maximum plasma concentration (Tmax), and; Terminal elimination half-life in plasma (t½)	baseline and up to 30 days	No
Secondary	serological characteristics	plasma glucose levels, insulin, C-peptide and glucagon levels will be measured	baseline and up to 30 days	No